Puri Avanti, Costanzo Filippo, Rivera Janny, Bujdos Jean
Psychiatry, Arnot Ogden Medical Center, Elmira, USA.
Psychiatry, Cleveland Clinic Akron General, Akron, USA.
Cureus. 2024 Jan 31;16(1):e53324. doi: 10.7759/cureus.53324. eCollection 2024 Jan.
We present the case of a 32-year-old woman who developed life-threatening catatonia in the setting of synthetic cannabis use. She was treated with high doses of lorazepam (up to 26 mg) and eventually transferred to receive electroconvulsive therapy (ECT). Synthetic cannabis poses a unique risk as it is widely available, difficult to regulate, and with adverse effects that are not well understood due to the presence of ever-changing chemical compounds. In this case report, we present one of the first cases of catatonia induced by first-time synthetic cannabinoids with no previous history of cannabis use disorder.
我们报告了一例32岁女性的病例,该患者在使用合成大麻的情况下出现了危及生命的紧张症。她接受了高剂量的劳拉西泮治疗(最高达26毫克),最终被转送去接受电休克治疗(ECT)。合成大麻带来了独特的风险,因为它广泛可得、难以监管,而且由于存在不断变化的化合物,其不良反应尚未得到充分了解。在本病例报告中,我们呈现了首例由首次使用合成大麻素诱发紧张症的病例,患者此前无大麻使用障碍病史。